Pinned straw:
Price seems to have rallied on that announcement.
Very binary outcome. 2nd time lucky hopefully
What is concerning for me is why does the addressable market beyond PE (Pulmonary Embolism) have to wait AFTER FDA approval of Technegas.
Why can't they cancel the diviidend and do some development work on expanding the addressable market beyond PE now?
Have to add the beyond PE strategy would probably be a big threat to the addressable market of 4DX as well.
Apologies if the question has been addressed but from listening to some podcasts, I don't think that beyond PE outcome of Cyclopharm has been properly answered.
I'm holding only a little because of the risks involved if the FDA issues another CRL.